Scientists have announced a significant breakthrough in Alzheimer’s research, revealing a new drug candidate that slows the progression of the disease by targeting protein accumulation in the brain. Clinical trials involving thousands of patients showed improved cognitive function and delayed symptom onset. Alzheimer’s, affecting millions globally, has long resisted effective treatment, making this development a hopeful milestone. Researchers caution that while promising, the drug requires further study before widespread use. This progress has ignited optimism in the medical community and among patients’ families, potentially paving the way for more effective therapies and early detection methods. The breakthrough highlights the importance of sustained investment in neurological research.
- charging reliability improving but satisfaction drops amid cost and complexity
- cancelled ev programs show automaker retreat
- tariffs cause polestar to report billion-dollar loss in q2
- dodge charger ev recall for being too quiet and unsafe
- polestar 3 recalled over water-damage risk in electrical system
- gm’s new adapters highlight ev charging standards confusion
- tesla model y auto window recall in australia over crush risk
- bmw recalls over 70k evs for possible power loss while driving
- uk warns charging must become as easy as filling up at the pump
- us states suing federal govt over ev infrastructure rollback
- limited battery recycling options raise environmental concerns
- electric car tire wear faster than expected
- charging station reliability problems drivers complain about
- battery replacement cost electric cars real numbers
- lack of charging stations in rural areas still a big problem